Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score 1.27
- Piotroski Score 4.00
- Grade Buy
- Symbol (AMLX)
- Company Amylyx Pharmaceuticals, Inc.
- Price $5.08
- Changes Percentage (-4.78%)
- Change -$0.25
- Day Low $4.88
- Day High $5.45
- Year High $19.95
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis. It is also developing AMX0035 for other neurodegenerative diseases. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
- Last Earnings 01/25/2018
- Ex-Dividend for 5/16 Dividend 03/28/2018
- Dividend Payable 04/02/2018
- Today N/A
- Next Earnings (Estimated) 11/07/2024
- Fiscal Year End N/A
- Average Stock Price Target $4.00
- High Stock Price Target $10.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$1.07
- Trailing P/E Ratio -1.65
- Forward P/E Ratio -1.65
- P/E Growth -1.65
- Net Income $49.27 M
Income Statement
Quarterly
Annual
Latest News of AMLX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Amylyx Pharmaceuticals (AMLX): Leading Nano Cap in Neurodegenerative Disease Treatments
An analysis of the best nano cap stocks to invest in highlights Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) as a top choice. The company focuses on developing treatments for neurodegenerative diseases...
By Yahoo! Finance | 1 week ago -
Director Karen Firestone Acquires 50,000 Shares of Amylyx Pharmaceuticals Inc (AMLX)
Amylyx Pharmaceuticals Inc focuses on developing treatments for neurodegenerative diseases. Recent insider buying by Karen Firestone reflects confidence in the company's future. Investors may consider...
By Yahoo! Finance | 1 month ago
